Hexapeptide-11

What is Hexapeptide-11?

Hexapeptide-11 is a synthetic hexapeptide with the sequence Phe-Val-Ala-Pro-Phe-Pro (FVAPFP), originally isolated from yeast (Saccharomyces cerevisiae) extracts and now produced synthetically for cosmetic use. It is distinguished from other cosmetic peptides (Argireline, Matrixyl, GHK-Cu, Decapeptide-12) by its proposed mechanism — rather than mimicking a neurotransmitter fragment (Argireline), a collagen propeptide (Matrixyl), or a tyrosinase inhibitor (Decapeptide-12), Hexapeptide-11 is framed as a proteostasis modulator: it upregulates the proteasome, autophagy machinery, molecular chaperones, and Nrf2-mediated antioxidant response in skin fibroblasts. This places it in a small category of cosmetic peptides with a cellular-housekeeping mechanism rather than a structural or enzymatic target. Clinical human efficacy data is limited; the strongest evidence is from in vitro and ex vivo fibroblast studies.

What Hexapeptide-11 Is Investigated For

Hexapeptide-11 is investigated as a topical cosmetic peptide with a distinctive mechanism — it activates the proteasome, autophagy machinery, molecular chaperones, and the Nrf2 antioxidant response in cultured skin fibroblasts. In normal human fibroblasts, it suppresses oxidative-stress-induced premature senescence and, in ex vivo skin deformation assays, improves elasticity. The mechanistic story is interesting because proteostasis decline is a recognized hallmark of aging, and most cosmetic peptides don't target this layer. The caveats are substantial: the published evidence comes primarily from one 2015 Gonos-group paper in Redox Biology, independent clinical replication is limited, and human RCT data for topical Hexapeptide-11 on measurable skin outcomes (wrinkle depth, elasticity, pigmentation) is essentially absent. It's best understood as a mechanistically interesting cosmetic ingredient with a thin clinical evidence base rather than a validated anti-aging therapeutic.

History & Discovery

Hexapeptide-11 traces to the long-standing cosmetic interest in yeast (Saccharomyces cerevisiae) extracts, which have been used in skincare for decades on the basis of qualitative observations about fermenter-workers' hands. The specific FVAPFP hexapeptide fraction was characterized and commercialized under the trade name Peptamide 6 by ingredient supplier Lipotec (now part of the Lubrizol/Croda cosmetic-actives ecosystem). The peptide remained a fairly obscure cosmetic ingredient until 2015, when Efstathios Gonos's group at the National Hellenic Research Foundation in Athens — a lab with a long track record in proteasome biology and cellular senescence — published a mechanistic paper in Redox Biology characterizing FVAPFP as a proteostasis activator in human diploid fibroblasts. That single paper remains the dominant primary-literature reference for the ingredient and is the source of essentially every "proteasome activator" and "autophagy activator" marketing claim now attached to Hexapeptide-11. Independent academic replication outside the original group has been sparse, and the ingredient continues to be more widely cited in cosmetic-industry literature than in dermatology journals.

How It Works

Hexapeptide-11 is a short peptide originally from yeast that appears to act like a "spring cleaning signal" for skin cells. It activates the cellular machinery that breaks down damaged proteins (proteasome and autophagy) and turns on the antioxidant defense system (Nrf2). In lab studies, this makes aged fibroblasts behave more like young ones. Whether that translates to visible skin improvement in humans hasn't been rigorously proven, but the mechanism is biologically interesting.

Hexapeptide-11 (FVAPFP) has been characterized primarily through in vitro studies in human diploid fibroblasts. Exposure to the peptide produces dose- and time-dependent upregulation of: (1) proteasomal subunit expression and peptidase activities, promoting degradation of damaged or oxidized proteins; (2) autophagy-lysosome system genes including BECN1, SQSTM1 (p62), and HDAC6, supporting turnover of protein aggregates and damaged organelles; (3) molecular chaperones HSF1, HSP27, HSP70, HSP90, and clusterin (CLU), which refold or escort damaged proteins; and (4) Nrf2 nuclear accumulation with downstream antioxidant response element (ARE) target gene activation. The net cellular effect is suppression of oxidative-stress-induced premature senescence and improved proteostasis capacity. The cellular receptor or primary target protein that mediates these broad transcriptional effects is not fully established — whether Hexapeptide-11 binds a specific surface receptor, translocates into cells, or acts indirectly via surface engagement is not definitively characterized. Ex vivo skin deformation assays suggest these cellular changes translate to improved biomechanical elasticity.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Hexapeptide-11:

• 01Independent academic replication of the 2015 Gonos-group proteostasis findings — the entire mechanistic case rests on one primary paper, and reproducibility across labs has not been established.
• 02Human RCT data on objective skin outcomes — no published double-blind, vehicle-controlled trial of Hexapeptide-11 in isolation measuring wrinkle depth, cutometer-based elasticity, collagen density by ultrasound, or transepidermal water loss in a representative aged-skin population.
• 03Skin penetration and dermal bioavailability — what fraction of applied FVAPFP actually reaches living fibroblasts in intact human skin, and how that fraction depends on formulation (liposomes, penetration enhancers, microneedling), remains essentially unmeasured in the public literature.
• 04Identity of the molecular target — whether Hexapeptide-11 binds a specific receptor, is internalized into cells, acts via a membrane-surface signaling event, or works indirectly through proteolytic fragments has not been resolved, leaving the structure-activity relationship undefined.
• 05Long-term safety of sustained proteasome and autophagy upregulation in epidermal and dermal cells — proteostasis pathways are tumor-suppressive in some contexts and tumor-permissive in others, and chronic pharmacological modulation of these systems in skin has not been studied.
• 06Comparative effect size against established cosmetic actives — head-to-head trials versus retinoids, vitamin C, niacinamide, or peer cosmetic peptides (Argireline, Matrixyl, GHK-Cu) on matched outcomes would let formulators and consumers price the ingredient against alternatives with stronger evidence.
• 07Whether the in vitro senescence-suppression finding translates to any measurable change in skin biopsy markers — senescence-associated β-galactosidase staining, p16/p21 expression, SASP cytokines — in humans treated topically.

Forms & Administration

Topical application in serums, creams, and comprehensive anti-aging formulations. Typically included at low concentrations alongside other actives. Skin penetration is a general challenge for hexapeptides — formulation (liposomal carriers, microneedling-assisted delivery) affects dermal bioavailability. Not for injection. Best used as part of a broader evidence-based skincare regimen rather than a stand-alone anti-aging intervention.

Common Questions

Who Hexapeptide-11 Is NOT For

Drug & Supplement Interactions

Documented drug interactions are not established — systemic absorption from a topical hexapeptide is expected to be low, and no clinical interaction studies have been published. The practical interaction concerns are dermatological rather than pharmacological. Layering Hexapeptide-11 with potent topical actives (prescription retinoids, hydroxy-acid peels at high concentration, benzoyl peroxide, topical corticosteroids) can drive cumulative irritation that obscures both efficacy and tolerability; introduce one active at a time on a several-week cadence. Acidic formulations (low-pH vitamin C serums, AHA/BHA exfoliants) can in theory destabilize peptide bonds via hydrolysis or alter charge state — most stability data for cosmetic peptides recommends separating peptide and low-pH layers by time of day (e.g., vitamin C in the morning, peptides at night) or by minutes within a routine. Oxidants and reactive metal-ion chelators in the same formulation may degrade the peptide during shelf life, which is a formulation-chemistry issue more than a user-level interaction. No clinically meaningful interactions with systemic prescription medications have been reported, consistent with negligible systemic exposure from cosmetic topical use.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions